Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 1/2020

Open Access 01-12-2020 | Tocilizumab | Research Letter

Efficacy of tocilizumab treatment in severely ill COVID-19 patients

Authors: Jie Zhao, Wei Cui, Bao-ping Tian

Published in: Critical Care | Issue 1/2020

Login to get access

Excerpt

The current coronavirus disease 2019 (COVID-19) pandemic induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already caused a global increase in hospitalizations and deaths. Unfortunately, effective medicines to fight this disease, especially in the severely ill patients, are still lacking [1]. Tocilizumab, a humanized monoclonal antibody used in rheumatoid arthritis treatment, might also be effective in treating severe COVID-19 as it could selectively target the interleukin-6 (IL-6) receptor [2]. Considering the uncertain efficacy of tocilizumab treatment in severe COVID-19, we conducted a systematic review and meta-analysis to clarify this added effect of tocilizumab. …
Literature
1.
2.
3.
4.
5.
6.
Metadata
Title
Efficacy of tocilizumab treatment in severely ill COVID-19 patients
Authors
Jie Zhao
Wei Cui
Bao-ping Tian
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Critical Care / Issue 1/2020
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/s13054-020-03224-7

Other articles of this Issue 1/2020

Critical Care 1/2020 Go to the issue

Letter

Do critically ill patients with AKI benefit from furosemide? Further real-word evidence from a large multi-center database

Correction

Correction to: Urine cell cycle arrest biomarkers distinguish poorly between transient and persistent AKI in early septic shock: a prospective, multicenter study

Letter

Expiratory flow limitation developed in ICU patients: relationship of fluid overload, respiratory mechanics, and outcome

Letter

ECCO2R and NIV-NAVA for stepwise early weaning in extremely severe COPD patients: a promising solution with details to be defined

Letter

Clostridioides difficile infection in the critically ill: what kind of therapy for refractory cases

Letter

The ARDSnet protocol may be detrimental in COVID-19